Optical

Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics

Retrieved on: 
Friday, March 8, 2024

Graphite Bio, Inc. (Nasdaq: GRPH) (“Graphite” or the “Company”) today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the “Merger”) with Lenz Therapeutics, Inc. (“LENZ”) pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the “Merger Agreement”).

Key Points: 
  • Graphite Bio, Inc. (Nasdaq: GRPH) (“Graphite” or the “Company”) today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the “Merger”) with Lenz Therapeutics, Inc. (“LENZ”) pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the “Merger Agreement”).
  • The special dividend, which the Company estimates will be $1.03 per share of Graphite’s common stock, will be payable in cash to the stockholders of record as of March 18, 2024.
  • The exact amount of the special dividend will be calculated after deducting certain cash amounts as set forth in the Merger Agreement.
  • The special dividend will not exceed an amount equal to $60 million, subject to the adjustments set forth in the Merger Agreement.

Nordic Eyewear Market Insights & Forecasts Report 2024-2028 with Competitive Analysis of Grand Vision, Synsam, Specsavers, Synologen, Optik Team, and Krogh Optikk - ResearchAndMarkets.com

Retrieved on: 
Friday, March 8, 2024

The "Nordic Eyewear Market (Sweden, Denmark, Norway & Finland): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nordic Eyewear Market (Sweden, Denmark, Norway & Finland): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.
  • The Nordic eyewear market can be categorized into the following sectors Spectacles, Contact Lenses, and Sunglasses.
  • In 2023, the dominant share of Nordic eyewear market was held by Sweden, followed by Denmark, Norway, and Finland.
  • The report provides a comprehensive analysis of the Nordic eyewear market.

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 7, 2024

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
  • “Throughout 2023, our team has continued to advance our clinical and preclinical pipeline of differentiated cell transplant programs,” stated Brian M. Culley, Lineage CEO.
  • Long-term follow-up of patients from the Phase 1/2a clinical study of OpRegen:
    Positive clinical data presented at 2023 Eyecelerator , 23rd EU RETINA Congress , and 2023 ARVO Annual Meetings.
  • Initiated development activities for hypoimmune pluripotent cell line for neurology indications under collaboration with Eterna Therapeutics.

STAAR Surgical to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Wednesday, March 6, 2024

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors at the following conferences:

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors at the following conferences:
    Oppenheimer Healthcare MedTech & Services Conference, Tuesday, March 12
    Management will also meet with investors in Shenzhen and Shanghai, China, from Monday, March 18 through Wednesday, March 20.
  • Investor participation is by invitation from each sponsoring brokerage firm.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, March 6, 2024

The Inducement Grants have been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan.

Key Points: 
  • The Inducement Grants have been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan.
  • The Inducement Grants were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date.
  • The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to each employee’s continued employment with Viridian through the applicable vesting dates.

Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone

Retrieved on: 
Wednesday, March 6, 2024

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants worldwide.

Key Points: 
  • Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants worldwide.
  • Recent, large-scale real-world data underscores the impact of Vivity on patients across the globe.
  • Vivity is available in more than 80 countries, including Australia, Brazil, Canada, China, France, Germany, Japan, India, Italy, South Korea, Spain, U.K. and U.S. Alcon offers a family of leading IOLs designed to meet the unique vision needs of patients, including Vivity and PanOptix®—the most implanted PCIOLs worldwide—as well as Monofocal and Toric options.
  • PanOptix surpassed 1M implants in early 2022, and is the most implanted trifocal worldwide.5,6 For more information, please visit www.alcon.ca .

MediPrint® Ophthalmics Announces Successful Completion of Its Phase 2b Glaucoma Clinical Study with Positive Results.

Retrieved on: 
Wednesday, March 6, 2024

MediPrint® Ophthalmics , a clinical-stage ocular drug delivery platform technology focused on transforming ocular drug delivery, announces the completion of its Glaucoma SIGHT-2, Phase 2b study.

Key Points: 
  • MediPrint® Ophthalmics , a clinical-stage ocular drug delivery platform technology focused on transforming ocular drug delivery, announces the completion of its Glaucoma SIGHT-2, Phase 2b study.
  • The Phase IIb trial was an active-controlled, randomized, dose-finding, multi-center study, evaluating the Company’s lead candidate (LL-BMT1) versus a control group on bimatoprost 0.01% ophthalmic solution.
  • SIGHT-2 study evaluated safety and efficacy of LL-BMT-1 in 28 patients diagnosed with open-angle Glaucoma for three weeks.
  • “The successful completion of the study is an important milestone as it validates our company’s technology and will help address significant unmet need for patients suffering from Glaucoma or Ocular Hypertension.

National Vision Holdings, Inc. Announces Participation in the UBS Global Consumer and Retail Conference

Retrieved on: 
Wednesday, March 6, 2024

National Vision Holdings, Inc. (NASDAQ: EYE) today announced that Reade Fahs, chief executive officer, and Melissa Rasmussen, chief financial officer, will participate in a fireside chat at the UBS Global Consumer and Retail Conference on Wednesday, March 13, 2024, at 1:00 p.m. Eastern Time.

Key Points: 
  • National Vision Holdings, Inc. (NASDAQ: EYE) today announced that Reade Fahs, chief executive officer, and Melissa Rasmussen, chief financial officer, will participate in a fireside chat at the UBS Global Consumer and Retail Conference on Wednesday, March 13, 2024, at 1:00 p.m. Eastern Time.
  • A live webcast of the fireside chat can be accessed on the “Investors” section of the Company’s website at www.nationalvision.com/investors .
  • The webcast will be archived and available on the website shortly after the event.

Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone

Retrieved on: 
Wednesday, March 6, 2024

Vivity is designed to simplify presbyopia correction, prioritizing patient satisfaction while minimizing surgeon and clinic chair time.

Key Points: 
  • Vivity is designed to simplify presbyopia correction, prioritizing patient satisfaction while minimizing surgeon and clinic chair time.
  • Recent, large-scale real-world data underscores the impact of Vivity on patients across the globe.
  • The Vivity Registry Study4+ includes patients with common mild comorbidities like glaucoma, dry eye and retinopathy/maculopathy, as well as post-refractive eyes.
  • PanOptix surpassed one million implants in early 2022, and is the most implanted trifocal worldwide.5,6 For more information, please visit www.ClareonIOL.com .

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Retrieved on: 
Tuesday, March 5, 2024

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11 at 2:00 p.m.

Key Points: 
  • Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11 at 2:00 p.m.
  • ET.
  • A live webcast of the fireside chat can be accessed under “Events and Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com .
  • A replay of the webcast will be available following the completion of the event.